BOULDER, Colo.--Genomica, a bioinformatics software company here, has received $7.5 million in initial funding to develop products for pharmaceutical, biotechnology, and agribusiness companies. The private investors include ARCH Venture Partners, Boulder Ventures, Falcon Technology Partners, Harris & Harris Group, INVESCO Trust, and Pegasus Technology Ventures. The software Genomica is developing offers such comprehensive, integrated bioinformatics tools as sequence, genetic, clinical, and functional analysis, and physical mapping. The company claims its software is unique in that it can maintain information on all aspects of the gene discovery process from clinical genetics work-up, to human genetics, genotyping, molecular cloning, and functional analysis of the gene sequence. The technology is compatible with UNIX, PC, and Macintosh systems.
In other news, Genomica--which opened for business last year--announced that Ralph Christoffersen, president and CEO of Ribozyme Pharmaceuticals, has joined its board of directors. He was previously a senior executive at SmithKline Beecham and Upjohn, and also served as president of Colorado State University.